US2020163936A1PendingUtilityA1

Oxo-M and 4-PPBP induction of tenogenic differentiation of perivascular tendon stem cells

Assignee: UNIV COLUMBIAPriority: Mar 16, 2016Filed: Jan 30, 2020Published: May 28, 2020
Est. expiryMar 16, 2036(~9.6 yrs left)· nominal 20-yr term from priority
B33Y 80/00A61L 27/56A61L 2300/412A61K 9/0024A61K 31/4015A61L 27/18A61P 31/00A61K 9/0019A61L 2300/622A61P 37/06A61K 9/16A61L 27/54A61K 31/196A61K 9/1635C04B 2111/00181A61K 9/2022A61K 9/14A61K 9/0097
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided herein are compositions including oxotremorine (e.g., oxotremorine methiodide or Oxo-M) and 4-PPBP (e.g., 4-PPBP maleate). Also provided are methods of treating a connective tissue defect in a subject with oxotremorine and 4-PPBP. In addition, provided are scaffolds and methods of making same that include multiple fibers that include Oxo-M, 4-PPBP, and optionally icariin or kartogenin.

Claims

exact text as granted — not AI-modified
1 - 18 . (canceled) 
     
     
         19 . A composition comprising:
 a polymeric microfiber produced by 3D printing; and   a plurality of microspheres encapsulating at least one agent;   
       wherein the microspheres are distributed through the polymeric microfiber and wherein the at least one agent comprises Oxo-M, 4-PPBP, kartogenin or Icariin, or any combination thereof. 
     
     
         20 . The composition of  claim 19 , wherein the microspheres comprise at least a first group of microspheres and a second group of microspheres;
 the first group of microspheres and the second group of microspheres comprise at least one agent; and   the first group of microspheres and the second group of microspheres comprise at least one different agent.   
     
     
         21 . The composition of  claim 19 , wherein the polymeric microfiber comprises polycarprolactone (PCL). 
     
     
         22 . The composition of  claim 19 , further comprising a visualizing agent. 
     
     
         23 . The composition of  claim 22 , wherein visualization agent is detectable with near infrared imaging. 
     
     
         24 . The composition of claim of  claim 22 , wherein the visualizing agent is a quantum dot. 
     
     
         25 - 35 . (canceled)

Join the waitlist — get patent alerts

Track US2020163936A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.